Overview

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Phase:
Phase 3
Details
Lead Sponsor:
AB Science
Treatments:
Imatinib Mesylate